Alnylam Pharmaceuticals
American biopharmaceutical company / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Alnylam?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics[3] for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.[4] In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.[5]
Quick Facts Company type, Traded as ...
Company type | Public |
---|---|
| |
Industry | Pharmaceutical |
Founded | 2002; 22 years ago (2002) |
Headquarters | Cambridge, Massachusetts, U.S. |
Key people | Yvonne Greenstreet (CEO) |
Revenue | US$1.83 billion (2023) US$1.04 billion (2022)[1] |
Number of employees | 2,100 (2023)[2] |
Website | alnylam |
Close